Opaleye Management Inc. 13D and 13G filings for Larimar Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-08-29 4:05 pm Purchase | 2025-08-29 | 13G | Larimar Therapeutics, Inc. LRMR | Opaleye Management Inc. | 4,110,000 4.800% | 157,591 (+3.99%) | Filing |
| 2025-04-16 5:11 pm Purchase | 2025-04-09 | 13G | Larimar Therapeutics, Inc. LRMR | Opaleye Management Inc. | 3,952,409 6.170% | 2,392,409 (+153.36%) | Filing |
| 2023-01-20 7:09 pm Purchase | 2022-12-31 | 13G | Larimar Therapeutics, Inc. LRMR | Opaleye Management Inc. | 1,560,000 3.610% | 616,298 (+65.31%) | Filing |
| 2022-02-18 4:32 pm Purchase | 2022-02-15 | 13G | Larimar Therapeutics, Inc. LRMR | Opaleye Management Inc. | 943,702 5.320% | 943,702 (New Position) | Filing |